Acepodia, Inc. (TPEX:6976)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
12.30
+0.20 (1.65%)
Apr 17, 2026, 1:38 PM CST
Market Cap7.25B -35.7%
Revenue (ttm)185.00K -56.7%
Net Income-754.40M
EPS-1.30
Shares Out582.22M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume594,776
Average Volume1,546,947
Open12.10
Previous Close12.10
Day's Range11.85 - 12.40
52-Week Range10.85 - 19.80
Beta0.58
RSI49.21
Earnings DateMay 13, 2026

About Acepodia

Acepodia, Inc. operates as a clinical stage biotechnology company. The company engages in developing cell therapies with its antibody cell conjugation (ACC) platform technology to address cancer care. It develops AD2C targeting GPC3 for HCC which is in preclinical stage; ACE 1831 targeting CD20 that is in phase 1 clinical trial; The company is based in Grand Cayman, the Cayman Islands. [Read more]

Industry Biotechnology
Sector Healthcare
CEO Shih-Chia Hsiao
Country Cayman Islands
Stock Exchange Taipei Exchange
Ticker Symbol 6976
Full Company Profile

Financial Performance

In 2025, Acepodia's revenue was 185,000, a decrease of -56.67% compared to the previous year's 427,000. Losses were -754.40 million, 51.9% more than in 2024.

Financial Statements